Key Points
- Insider sale: EVP Craig Hopkinson sold 3,748 shares at $30 each for $112,440, reducing his stake by 5.39% to 65,740 shares valued at about $1.97M (filed with the SEC).
- Company results and analyst view: Alkermes beat Q results with $0.49 EPS (vs. $0.41 est.) and $394.2M revenue, set FY2025 guidance of 1.36–1.47 EPS, and carries a consensus "Moderate Buy" with an average price target near $44.69.
Alkermes plc (NASDAQ:ALKS - Get Free Report) EVP Craig Hopkinson sold 3,748 shares of the firm's stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $30.00, for a total value of $112,440.00. Following the transaction, the executive vice president owned 65,740 shares of the company's stock, valued at $1,972,200. This trade represents a 5.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Alkermes Price Performance
Shares of NASDAQ:ALKS opened at $29.52 on Friday. The firm has a market capitalization of $4.87 billion, a PE ratio of 14.61, a price-to-earnings-growth ratio of 1.41 and a beta of 0.49. The firm's 50-day moving average is $30.45 and its two-hundred day moving average is $29.37. Alkermes plc has a 1 year low of $25.17 and a 1 year high of $36.45.
Alkermes (NASDAQ:ALKS - Get Free Report) last posted its quarterly earnings data on Tuesday, October 28th. The company reported $0.49 EPS for the quarter, beating the consensus estimate of $0.41 by $0.08. The business had revenue of $394.19 million during the quarter, compared to analyst estimates of $355.23 million. Alkermes had a net margin of 22.27% and a return on equity of 21.81%. The business's revenue for the quarter was up 4.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.73 earnings per share. Alkermes has set its FY 2025 guidance at 1.360-1.470 EPS. Analysts expect that Alkermes plc will post 1.31 EPS for the current fiscal year.
Analyst Ratings Changes
ALKS has been the subject of several recent research reports. Needham & Company LLC raised their price target on shares of Alkermes from $43.00 to $44.00 and gave the company a "buy" rating in a research report on Wednesday, October 29th. Jefferies Financial Group set a $56.00 price objective on Alkermes and gave the company a "buy" rating in a research note on Tuesday, October 28th. Wall Street Zen lowered Alkermes from a "strong-buy" rating to a "buy" rating in a report on Sunday, November 9th. Truist Financial boosted their target price on Alkermes from $50.00 to $55.00 and gave the stock a "buy" rating in a research note on Monday, November 17th. Finally, JPMorgan Chase & Co. upped their price target on Alkermes from $34.00 to $35.00 and gave the stock a "neutral" rating in a report on Tuesday, September 9th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have issued a Hold rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $44.69.
View Our Latest Stock Report on ALKS
Hedge Funds Weigh In On Alkermes
A number of institutional investors and hedge funds have recently modified their holdings of the company. Diversified Trust Co boosted its position in shares of Alkermes by 0.8% during the 2nd quarter. Diversified Trust Co now owns 44,232 shares of the company's stock worth $1,265,000 after acquiring an additional 372 shares in the last quarter. Orion Porfolio Solutions LLC raised its position in shares of Alkermes by 4.5% during the 3rd quarter. Orion Porfolio Solutions LLC now owns 8,762 shares of the company's stock worth $263,000 after acquiring an additional 376 shares in the last quarter. Quantbot Technologies LP raised its position in shares of Alkermes by 54.5% during the 1st quarter. Quantbot Technologies LP now owns 1,091 shares of the company's stock worth $36,000 after acquiring an additional 385 shares in the last quarter. Horizon Investments LLC lifted its stake in Alkermes by 0.9% during the third quarter. Horizon Investments LLC now owns 43,002 shares of the company's stock worth $1,290,000 after purchasing an additional 387 shares during the last quarter. Finally, AMG National Trust Bank lifted its stake in Alkermes by 0.6% during the third quarter. AMG National Trust Bank now owns 60,175 shares of the company's stock worth $1,805,000 after purchasing an additional 388 shares during the last quarter. Institutional investors and hedge funds own 95.21% of the company's stock.
About Alkermes
(
Get Free Report)
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
